Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Standards of Care II

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Standards of Care I

Standards of Care I

Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma.

Analytical chemistry·2014

Same author

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Blood·2014

Same author

Daratumumab granted breakthrough drug status.

Expert opinion on investigational drugs·2014

Same author

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.

International journal of oncology·2014

Same author

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Blood·2014

Same author

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Nature communications·2014

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Multiple myeloma clinical practice guidelines in oncoloqy.

Kenneth C Anderson¹,

¹Dana-Farber/Partners CancerCare Dana-Farber Cancer Institute, USA.

Journal of the National Comprehensive Cancer Network : JNCCN

|October 3, 2009

Summary

Multiple myeloma, though sensitive to chemotherapy and radiation, is currently incurable. Treatment guidelines focus on optimizing therapy and supportive care, prioritizing clinical research protocols for patients.

Area of Science:

Hematology
Oncology
Clinical Medicine

Background:

Multiple myeloma is a hematologic malignancy with current limitations in achieving a complete cure.
Existing treatments like chemotherapy and radiation therapy demonstrate sensitivity but not eradication of the disease.

Purpose of the Study:

To develop optimized treatment algorithms for multiple myeloma.
To integrate supportive care strategies for enhancing patient quality of life.
To guide the inclusion of patients in clinical research protocols for incurable myeloma.

Main Methods:

Compilation of published data and clinical expertise.
Development of evidence-based treatment recommendations.
Identification of criteria for patient enrollment in clinical trials.

Related Experiment Videos

Last Updated: Jun 19, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Main Results:

Established treatment algorithms for multiple myeloma management.
Highlighted the importance of supportive care alongside disease-directed therapy.
Defined clinical scenarios suitable for research protocol participation.

Conclusions:

Optimized treatment algorithms can improve outcomes for multiple myeloma patients.
A comprehensive approach including supportive care is crucial for incurable cancers.
Clinical research remains a vital component in advancing multiple myeloma treatment.